Data from the Swedish registry, Czech registry, COMPLETE registry, and T-cell Project all suggest ASCT is underutilized in patients with PTCL.

ASCT may be underused, in part, because it isn’t clear if the treatment provides a benefit in PTCL. Data from the Swedish registry and T-cell Project suggested ASCT can improve survival, but the Czech registry data showed no survival difference between ASCT recipients and nonrecipients.

Likewise, the COMPLETE registry showed no significant differences in median PFS and OS between ASCT recipients and nonrecipients. However, the data indicated that ASCT may provide a survival benefit in some patients, such as those with advanced disease.

Read more: [ Ссылка ]

свернуть